Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged ≥ 18 and \< 71 years (Note: HIV-negative subjects with MDS must be aged \<50 at the time of signing the informed consent form) * Diagnosed with * Acute leukemias or T-lymphoblastic lymphoma (T-LBL) in 1st or subsequent CR * Acute lymphocytic leukemia (ALL) or T-LBL as defined by the following: * \< 5% blasts in the bone marrow * Normal maturation of all cellular components in the bone marrow * No currently active extramedullary disease (EMD) (e.g., central nervous system (CNS), soft tissue disease) * ANC ≥ 1,000/mm3 * Acute myeloid leukemia (AML) defined by the following: * \< 5% blasts in the bone marrow * No blasts with Auer rods * Normal maturation of all cellular components in the bone marrow * No currently active EMD (e.g., CNS, soft tissue disease) * ANC ≥ 1,000/mm3 * Acute biphenotypic leukemia (ABL)/Acute undifferentiated leukemia (AUL) defined by the following: * \< 5% blasts in the bone marrow * Normal maturation of all cellular components in the bone marrow * No currently active EMD (e.g., CNS, soft tissue disease) * ANC ≥ 1,000/mm3 * Myleodysplastic Syndromes (MDS), fulfilling the following criteria: * Subjects with de novo MDS who have or have previously had Intermediate-2 or High-risk disease as determined by the IPSS. Current Intermediate-2 or High- risk disease …